commsec analysis

STRATEGY ANALYSIS
VCR's strategy is to be a pre-eminent supplier of cardiac assist
systems for people suffering end-stage heart failure. This will be
achieved to through successful commercialisation of the VentrAssist
system.
Recruitment in the US clinical trials is expected to grow rapidly over
the next year as the number of medical centres trained and
implanting devices will increase from four to more than 20 by
mid-2008. VCR´s strategy is to have US centres participate in both
the BTT and DT Trials, which will provide operating efficiencies
and optimal clinical results. The European market is, however,
underdeveloped compared to the US. Therefore the company´s
strategy is to continue to take market share from competitors and
also to contribute to the growth of the market by recruiting new
LVAD centres, and working to improve reimbursement. The focus
will be on key markets that have a good short to medium term return
on investment.
(Last Updated: 22/10/07

The following statement was made on the 5th Oct,07;

Ventracor Chief Executive Officer Peter Crosby said: “We are pleased with the growing momentum as the number of centres has grown from the original four to now 23 centres working through the process of Institutional Review Board (ethics committee) approval, training, and site initiation, which includes eight sites ready to enroll in the BTT trial, and six sites ready to enroll in the DT trial. We anticipate the implant rate will increase in the coming months as more centers become active.”